ODM-212 for Pancreatic Cancer

(TEADCO Trial)

This trial tests a new drug, ODM-212, to evaluate its effectiveness when combined with other treatments for various cancers, including pancreatic cancer, mesothelioma, and NSCLC with a KRAS mutation. The goal is to determine the optimal dose and understand how these combinations can combat tumors. Individuals with metastatic pancreatic cancer eligible for nab-paclitaxel and gemcitabine treatments might be suitable candidates for this trial. As a Phase 1 trial, this research aims to understand how the treatment works in people, providing an opportunity to be among the first to receive this new drug.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have had chemotherapy, immunotherapy, or other anti-cancer treatments within 2 weeks before starting the trial. It's best to discuss your specific medications with the trial team.

Research has shown that combining ODM-212 with gemcitabine and nab-paclitaxel is generally well-tolerated. Studies on gemcitabine and nab-paclitaxel, both chemotherapy drugs, have indicated their safety and effectiveness in treating pancreatic cancer. Patients in these studies experienced manageable side effects, suggesting a favorable safety profile.

Researchers are excited about ODM-212 for pancreatic cancer because it introduces a new mechanism of action that targets cancer cells differently than standard chemotherapy options like gemcitabine and nab-paclitaxel. While traditional treatments often focus on directly killing rapidly dividing cells, ODM-212 is designed to disrupt specific pathways that cancer cells rely on to grow and spread. This targeted approach could potentially lead to more effective and less toxic treatments, offering hope for improved outcomes in a disease that has historically been challenging to treat. Additionally, in combination with other agents like gemcitabine, nab-paclitaxel, and sotorasib, ODM-212 may enhance the effectiveness of existing therapies, providing a multifaceted attack on cancer cells.

Research has shown that combining gemcitabine and nab-paclitaxel effectively treats pancreatic cancer. In studies, patients receiving this combination lived an average of 13.87 months, longer than those taking gemcitabine alone. The time before disease progression improved to 5.37 months, compared to 2.80 months with only gemcitabine. The overall response rate, which measures tumor shrinkage or disappearance, was about 36.6%. In this trial, one treatment arm will evaluate ODM-212 combined with gemcitabine and nab-paclitaxel for pancreatic cancer, aiming to assess its potential benefits.¹²⁶⁷⁸